SCHEMBL6835870

SCHEMBL6835870

Cc1ccc2c(c1)-c1c(nc(-c3ccccn3)n1O)CCC2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 6/20 0.54
METAP2 P50579 1/20 0.38
METAP1 P53582 1/20 0.38
CBFB Q13951 1/20 0.38
PKM P14618 3/20 0.37
RAB9A P51151 3/20 0.37
NPC1 O15118 2/20 0.37
PARP1 P09874 1/20 0.36
PARP10 Q53GL7 1/20 0.36
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 2/20 0.36
TP53 P04637 1/20 0.36
GAA P10253 3/20 0.34
MAPT P10636 2/20 0.34
POLB P06746 1/20 0.34
HCRTR1 O43613 2/20 0.34
HCRTR2 O43614 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6837099 0.88 NPY5R (0.53) NPY5RMETAP2METAP1CBFBPARP1
SCHEMBL6836913 0.87 NPY5R (0.55) NPY5RMETAP1RAB9ANPC1PDE10A
SCHEMBL6834554 0.87 NPY5R (0.47) NPY5RRAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL6835192 0.80 NPY5R (0.50) NPY5RPARP1PARP10ALDH1A1
SCHEMBL6835215 0.79 NPY5R (0.53) NPY5RRAB9ANPC1ALDH1A1KDM4E
SCHEMBL6835219 0.74 NPY5R (0.68) NPY5RMETAP2METAP1CBFBPKM
SCHEMBL6834506 0.71 NPY5R (0.48) NPY5RRAB9ANPC1ALDH1A1KDM4E
SCHEMBL6835176 0.70 NPY5R (0.51) NPY5RALDH1A1KDM4EHPGDHSD17B10
SCHEMBL6831686 0.69 KDM4E (0.48) NPY5RRAB9ANPC1ALDH1A1KDM4E
SCHEMBL6831684 0.69 NPY5R (0.45) NPY5RRAB9ANPC1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040198791-A1 Fused imidazole derivative FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198791-A1 Fused imidazole derivative H1-0, H1-5, H1-3 NPY5R 983/4885METAP2 4294/4885METAP1 4198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.